Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADIL NASDAQ:ALZN NASDAQ:MYNZ NASDAQ:SRNE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADILAdial Pharmaceuticals$0.35-0.3%$0.40$0.22▼$1.30$7.62M1.083.70 million shs199,650 shsALZNAlzamend Neuro$2.43+1.0%$2.56$2.06▼$17.10$7.58M-0.3617,500 shs43,518 shsMYNZMainz Biomed$1.61$1.71$1.30▼$16.04$7.37M0.25177,726 shs15,887 shsSRNESorrento Therapeutics$0.01-5.7%$0.00$0.00▼$0.10$2.76M1.08125,218 shs15,373 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADILAdial Pharmaceuticals0.00%0.00%-7.92%+33.08%-66.67%ALZNAlzamend Neuro0.00%-0.41%-3.61%-18.64%-84.22%MYNZMainz Biomed0.00%-3.01%-8.00%+15.83%-83.44%SRNESorrento Therapeutics0.00%+42.86%+16.28%+127.27%-28.57%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADILAdial Pharmaceuticals$0.35-0.3%$0.40$0.22▼$1.30$7.62M1.083.70 million shs199,650 shsALZNAlzamend Neuro$2.43+1.0%$2.56$2.06▼$17.10$7.58M-0.3617,500 shs43,518 shsMYNZMainz Biomed$1.61$1.71$1.30▼$16.04$7.37M0.25177,726 shs15,887 shsSRNESorrento Therapeutics$0.01-5.7%$0.00$0.00▼$0.10$2.76M1.08125,218 shs15,373 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADILAdial Pharmaceuticals0.00%0.00%-7.92%+33.08%-66.67%ALZNAlzamend Neuro0.00%-0.41%-3.61%-18.64%-84.22%MYNZMainz Biomed0.00%-3.01%-8.00%+15.83%-83.44%SRNESorrento Therapeutics0.00%+42.86%+16.28%+127.27%-28.57%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADILAdial Pharmaceuticals 3.00Buy$8.002,185.71% UpsideALZNAlzamend Neuro 3.00Buy$45.001,775.00% UpsideMYNZMainz Biomed 2.50Moderate Buy$14.00769.57% UpsideSRNESorrento Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest SRNE, ADIL, MYNZ, and ALZN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/21/2025ALZNAlzamend NeuroAscendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$180.00 ➝ $45.008/20/2025ADILAdial PharmaceuticalsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold(Data available from 9/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADILAdial PharmaceuticalsN/AN/AN/AN/A$0.64 per shareN/AALZNAlzamend NeuroN/AN/AN/AN/A$4.95 per shareN/AMYNZMainz Biomed$890K8.29N/AN/A$2.61 per share0.62SRNESorrento Therapeutics$60.32M0.05N/AN/AN/A∞Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADILAdial Pharmaceuticals-$13.20M-$1.05N/AN/AN/AN/A-191.31%-153.59%11/12/2025 (Estimated)ALZNAlzamend Neuro-$4.51MN/A0.00N/AN/AN/A-151.24%-124.17%12/10/2025 (Estimated)MYNZMainz Biomed-$21.65M-$65.60N/AN/AN/AN/AN/AN/AN/ASRNESorrento Therapeutics-$572.84MN/A0.00∞N/AN/AN/AN/AN/ALatest SRNE, ADIL, MYNZ, and ALZN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025ADILAdial Pharmaceuticals-$0.22-$0.18+$0.04-$0.18N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADILAdial PharmaceuticalsN/AN/AN/AN/AN/AALZNAlzamend NeuroN/AN/AN/AN/AN/AMYNZMainz BiomedN/AN/AN/AN/AN/ASRNESorrento TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADILAdial PharmaceuticalsN/A5.025.02ALZNAlzamend NeuroN/A6.036.03MYNZMainz Biomed0.141.321.26SRNESorrento TherapeuticsN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADILAdial Pharmaceuticals16.41%ALZNAlzamend Neuro49.61%MYNZMainz BiomedN/ASRNESorrento Therapeutics0.02%Insider OwnershipCompanyInsider OwnershipADILAdial Pharmaceuticals4.26%ALZNAlzamend Neuro30.21%MYNZMainz BiomedN/ASRNESorrento Therapeutics2.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADILAdial Pharmaceuticals2021.83 million20.90 millionNo DataALZNAlzamend Neuro43.14 million2.19 millionNo DataMYNZMainz Biomed304.58 millionN/ANot OptionableSRNESorrento Therapeutics800551.28 million536.95 millionNo DataSRNE, ADIL, MYNZ, and ALZN HeadlinesRecent News About These CompaniesSorrento Therapeutics Inc (SRNE) - Investing.comJuly 3, 2025 | investing.comSRNE Sorrento Therapeutics, Inc. - Seeking AlphaJune 29, 2025 | seekingalpha.comSorrento Therapeutics Stock Price, Quotes and Forecasts | OTC:SRNE | BenzingaApril 19, 2025 | benzinga.comSorrento Shareholders Lose Discovery Bid Over Judge RelationshipMarch 28, 2025 | news.bloomberglaw.comNScilex says bankruptcy court extends lockup period on shares of Scilex dividendJanuary 31, 2025 | markets.businessinsider.comDSI Introduces Westbury Sorrento Aluminum Railing with Bold Distinctive Mesh Stainless Steel InfillsOctober 24, 2024 | newsfilecorp.comNSorrento enrols 60 of 80-patient Phase II target for abivertinib in Covid-19; futility analysis potentially in a month, CEO saysAugust 20, 2024 | msn.comSorrento Resources to Sell Three Newfoundland Properties to Gold HunterMay 29, 2024 | newsfilecorp.comNSorrento Therapeutics Inc (SRNE)May 25, 2024 | investing.comSorrento Resources Announces Appointment of Alex Bugden as a Director and Qualified PersonMay 8, 2024 | newsfilecorp.comNDSI Introduces Westbury(R) Sorrento Aluminum and Stainless Steel Mesh RailingMay 1, 2024 | newsfilecorp.comNSorrento Therapeutics Inc SRNEApril 26, 2024 | morningstar.comMSorrento Therapeutics Wins Appeal Over Covid Treatment RemarksMarch 27, 2024 | news.bloomberglaw.comNSorrento Therapeutics Wins Appeal Over Covid Treatment RemarksMarch 27, 2024 | news.bloomberglaw.comNSorrento Defeats DOJ Effort to Move Bankruptcy Out of Texas (1)March 12, 2024 | news.bloomberglaw.comNJudge Declines to Dismiss Sorrento Therapeutics Bankruptcy CaseMarch 12, 2024 | wsj.comVirpax Pharmaceuticals Announces Proposed Settlement of Litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc.February 27, 2024 | tmcnet.comVirpax Pharmaceuticals Announces Proposed Settlement of Litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc.February 27, 2024 | businesswire.comSorrento TherapeuticsFebruary 7, 2024 | pharmaphorum.comP5 Sanders Cove, Sorrento WA 6020January 18, 2024 | domain.com.auDNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSRNE, ADIL, MYNZ, and ALZN Company DescriptionsAdial Pharmaceuticals NASDAQ:ADIL$0.35 0.00 (-0.29%) As of 11:35 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.Alzamend Neuro NASDAQ:ALZN$2.42 +0.03 (+1.04%) As of 11:40 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.Mainz Biomed NASDAQ:MYNZ$1.61 0.00 (0.00%) As of 11:27 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. The company was founded in 2008 and is based in Mainz, Germany.Sorrento Therapeutics NASDAQ:SRNE$0.0050 0.00 (-5.66%) As of 11:16 AM EasternSorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company, develops a portfolio of next-generation treatments for three therapeutic areas: cancer, infectious disease,and pain. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host disease. The company develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis pain treatment; and ZTlido, a lidocaine topical system for the treatment of post-herpetic neuralgia. It engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain condition; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia. It has collaboration with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; and Mayo Clinic for Phase Ib pilot study using sofusa lymphatic drug delivery technology to deliver Ipilimumab in patient with melanoma. The company was founded in 2006 and is based in San Diego, California. On February 13, 2023, Sorrento Therapeutics, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas. The plan was later approved as Chapter 11 liquidation on November 30, 2023. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Banks Boost Gold Forecasts: One Sees +30% Bull-Case Potential These 3 Stocks Boosting Buybacks Have Rallying Potential GameStop Partying Like It’s 2021: What’s Behind Its 2025 Rebound? Hims & Hers Stock Pushes to Highs on Healthcare Rate Cut Frenzy FedEx Delivers Good News: The Bottom Is in for This Stock Tesla: 2 Reasons to Love Musk's $1B Buy, 1 Reason to Be Bearish Berkshire-Backed Lennar Slides After Weak Q3 Earnings Azure Leads While AI Excitement Fuels Microsoft Stock Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
